Clinical Trials
11
Active:1
Completed:8
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)โข Click on a phase to view related trials
Phase 1
6 (54.5%)Phase 3
3 (27.3%)Phase 2
2 (18.2%)Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
Phase 3
Recruiting
- Conditions
- Peptic Ulcer
- Interventions
- Drug: Lanston Capsule 15 mgDrug: JP-1366 10 mgDrug: Lanston Capsule 15 mg placeboDrug: JP-1366 10 mg placebo
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 364
- Registration Number
- NCT06439563
- Locations
- ๐ฐ๐ท
Konkuk University Medical Center, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JP-1366 20mg tabletDrug: JP-1366 20mg capsule
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05814809
- Locations
- ๐ฐ๐ท
Yangji Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JP-1366 20mg tablet
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05712681
- Locations
- ๐ฐ๐ท
Asan Medical Central, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05475184
- Locations
- ๐ฐ๐ท
National Cancer Center, Gyeonggi-do, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Onconic Therapeutics Inc.
- Target Recruit Count
- 329
- Registration Number
- NCT05448001
- Locations
- ๐ฐ๐ท
Korea University Kuro Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- Next
News
No news found